Literature DB >> 24944492

Should peri-gastrectomy gastric acidity be our focus among gastric cancer patients?

Lei Huang1, A-Man Xu1, Tuan-Jie Li1, Wen-Xiu Han1, Jing Xu1.   

Abstract

AIM: To investigate the necessity and correctness of acid suppression pre- and post-gastrectomy among gastric carcinoma (GC) patients.
METHODS: From June 2011 to April 2013, 99 patients who were diagnosed with GC or adenocarcinoma of the gastroesophageal junction (type II or III) and needed surgical management were enrolled. They all underwent gastrectomy by the same operators [35 undergoing total gastrectomy (TG) plus Roux-en-Y reconstruction, 34 distal gastrectomy (DG) plus Billroth I reconstruction, and 30 proximal gastrectomy (PG) plus gastroesophagostomy]. We collected and analyzed their gastrointestinal juice and tissues from the pre-operational day to the 5(th) day post-operation, and 6 mo post-surgery. Gastric pH was detected with a precise acidity meter. Gastric juice contents including potassium, sodium and bicarbonate ions, urea nitrogen, direct and indirect bilirubin, and bile acid were detected using Automatic Biochemical Analyzer. Data regarding tumor size, histological type, tumor penetration and tumor-node-metastasis (TNM) stage were obtained from the pathological records. Reflux symptoms pre- and 6 mo post-gastrectomy were evaluated by reflux disease questionnaire (RDQ) and gastroesophageal reflux disease questionnaire (GERD-Q). SPSS 16.0 was applied to analyze the data.
RESULTS: Before surgery, gastric pH was higher than the threshold of hypoacidity (4.25 ± 1.45 vs 3.5, P = 0.000), and significantly affected by age, tumor size and differentiation grade, and potassium and bicarbonate ions; advanced malignancies were accompanied with higher pH compared with early ones (4.49 ± 1.31 vs 3.66 ± 1.61, P = 0.008). After operation, gastric pH in all groups was of weak-acidity and significantly higher than that pre-gastrectomy; on days 3-5, comparisons of gastric pH were similar between the 3 groups. Six months later, gastric pH was comparable to that on days 3-5; older patients were accompanied with higher total bilirubin level, indicating more serious reflux (r = 0.238, P = 0.018); the TG and PG groups had higher RDQ (TG vs DG: 15.80 ± 5.06 vs 12.26 ± 2.14, P = 0.000; PG vs DG: 15.37 ± 3.49 vs 12.26 ± 2.14, P = 0.000) and GERD-Q scores (TG vs DG: 10.54 ± 3.16 vs 9.15 ± 2.27, P = 0.039; PG vs DG: 11.00 ± 2.07 vs 9.15 ± 2.27, P = 0.001) compared with the DG group; all gastric juice contents except potassium ion significantly rose; reflux symptom was significantly associated with patient's body mass index, direct and indirect bilirubin, and total bile acid, while pH played no role.
CONCLUSION: Acidity is not an important factor causing unfitness among GC patients. There is no need to further alkalify gastrointestinal juice both pre- and post-gastrectomy.

Entities:  

Keywords:  Acidity; Gastrectomy; Gastric carcinoma; Gastrointestinal juice; Reflux

Mesh:

Year:  2014        PMID: 24944492      PMCID: PMC4051941          DOI: 10.3748/wjg.v20.i22.6981

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  32 in total

1.  The augmented histamine test with special reference to achlorhydria.

Authors:  S T CALLENDER; F P RETIEF; L J WITTS
Journal:  Gut       Date:  1960-12       Impact factor: 23.059

2.  Gastric cancer detection using gastric juice pepsinogen and melanoma-associated gene RNA.

Authors:  Hyun-Dong Chae; In-Ho Kim; Geon Ho Lee; Im-Hee Shin; Hun-Suk Suh; Chang-Ho Jeon
Journal:  Am J Clin Pathol       Date:  2013-08       Impact factor: 2.493

3.  Importance of duodenogastric reflux in gastro-oesophageal reflux disease.

Authors:  M Fein; J Maroske; K-H Fuchs
Journal:  Br J Surg       Date:  2006-12       Impact factor: 6.939

4.  Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis.

Authors:  P O Katz; G G Ginsberg; P E Hoyle; M B Sostek; J T Monyak; D G Silberg
Journal:  Aliment Pharmacol Ther       Date:  2007-03-01       Impact factor: 8.171

5.  Heartburn treatment in primary care: randomised, double blind study for 8 weeks.

Authors:  J G Hatlebakk; A Hyggen; P H Madsen; P O Walle; T Schulz; P Mowinckel; T Bernklev; A Berstad
Journal:  BMJ       Date:  1999-08-28

6.  Why are patients prescribed proton pump inhibitors? Retrospective analysis of link between morbidity and prescribing in the General Practice Research Database.

Authors:  J N Bashford; J Norwood; S R Chapman
Journal:  BMJ       Date:  1998-08-15

7.  Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease.

Authors:  M Cicala; S Emerenziani; R Caviglia; M P L Guarino; P Vavassori; M Ribolsi; S Carotti; T Petitti; F Pallone
Journal:  Aliment Pharmacol Ther       Date:  2003-09-15       Impact factor: 8.171

8.  Do acid and bile reflux into the esophagus simultaneously? Temporal relationship between duodenogastro-esophageal reflux and esophageal pH.

Authors:  Rok Orel; Gaj Vidmar
Journal:  Pediatr Int       Date:  2007-04       Impact factor: 1.524

9.  Rising incidence of reflux oesophagitis in patients undergoing upper gastrointestinal endoscopy.

Authors:  R J L F Loffeld; A B M M van der Putten
Journal:  Digestion       Date:  2003-11-28       Impact factor: 3.216

10.  The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole.

Authors:  D Armstrong; N J Talley; K Lauritsen; B Moum; T Lind; H Tunturi-Hihnala; T Venables; J Green; M A Bigard; J Mössner; O Junghard
Journal:  Aliment Pharmacol Ther       Date:  2004-08-15       Impact factor: 8.171

View more
  5 in total

Review 1.  Detection of digestive malignancies and post-gastrectomy complications via gastrointestinal fluid examination.

Authors:  Lei Huang; Aman Xu
Journal:  Front Med       Date:  2017-03-02       Impact factor: 4.592

2.  Adenocarcinoma of esophagogastric junction: controversial classification, surgical management, and clinicopathology.

Authors:  Lei Huang; A-Man Xu
Journal:  Chin J Cancer Res       Date:  2014-06       Impact factor: 5.087

3.  Inhibitory effects of isocryptotanshinone on gastric cancer.

Authors:  Zhang-Ming Chen; Lei Huang; Miao-Miao Li; Lei Meng; Song-Cheng Ying; A-Man Xu
Journal:  Sci Rep       Date:  2018-06-18       Impact factor: 4.379

4.  Distal Gastrectomy with Billroth II Reconstruction is Associated with Oralization of Gut Microbiome and Intestinal Inflammation: A Proof-of-Concept Study.

Authors:  Angela Horvath; Augustinas Bausys; Rasa Sabaliauskaite; Eugenijus Stratilatovas; Sonata Jarmalaite; Burkhard Schuetz; Philipp Stiegler; Rimantas Bausys; Vanessa Stadlbauer; Kestutis Strupas
Journal:  Ann Surg Oncol       Date:  2020-06-05       Impact factor: 5.344

Review 5.  Re-thinking the possible interaction between proton pump inhibitors and capecitabine.

Authors:  Soo Hee Jeong; Lara Molloy; Edmond Ang; Nuala Helsby
Journal:  Cancer Chemother Pharmacol       Date:  2022-09-13       Impact factor: 3.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.